Acrivon Therapeutics CEO proposes sale of 1,276 shares
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Acrivon Therapeutics, Inc. CEO and director Peter Blume-Jensen gave notice of a proposed sale of 1,276 common shares, with an approximate sale date of November 17, 2026, and an aggregate market value of $1,824.68. The notice lists 42,911,680 common shares outstanding and records his acquisition of 3,756 common shares on November 14, 2026, through settlement of vested RSUs issued under an S-8 Registration Plan.
The past-three-months table lists sales by Peter Blume-Jensen of 1,229 shares on August 18, 2026, for $2,470.29 and 14,036 shares on August 25, 2026, for $30,969.08; it also lists Kristina Masson's sale of 484 shares on August 18, 2026, for $972.84. The remarks state that shares were sold automatically to satisfy mandatory tax withholding upon vesting of restricted stock units.
Key Figures
Key Terms
restricted stock units financial
S-8 Registration Plan regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.